Open AccessPreclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas
Author(s) -
Joost van der Hoek,
Steven W. J. Lamberts,
Leo J. Hofland
Publication year - 2007
Publication title -
european journal of endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.897
H-Index - 148
eISSN - 1479-683X
pISSN - 0804-4643
DOI - 10.1530/eje.1.02350
Subject(s) - somatostatin , endocrine system , somatostatin receptor , receptor , medicine , endocrinology , neuroscience , bioinformatics , hormone , biology
The patho-physiological role of somatostatin receptor subtypes (sst) in neuro endocrine diseases has gained enhanced scientific interest in the past few years. The development of novel somatotropin-release inhibiting factor analogs, both sst-specific and universal ligands, seem promising as a tool to further increase fundamental insights in sst function. Eventually, this research should result in novel medical therapeutic opportunities in patients suffering from neuro-endocrine diseases. In the present review, the functional role of sst in all types of pituitary adenomas, based on recent preclinical and clinical studies, is being discussed.